International

As your business becomes increasingly global, you need counsel who understand your legal and business issues and the challenges facing those doing business in the international marketplace. Clients, based in the United States and around the globe, regularly turn to Mintz Levin to handle matters of an international flavor.

We have successfully represented international clients for decades, helping them achieve their business objectives and conduct transactions spanning the globe. Our attorneys are well-versed in the nuances of doing business outside of the United States and representing overseas companies doing business in North America. Similarly, we are experienced in explaining the expectations and requirements of US investors to overseas clients and counsel, and we know how to develop solutions for the sometimes conflicting regulatory issues and customs.

No matter the locale, we can efficiently and effectively manage your transaction.

Quick Facts


Areas of Focus

Sort by: Name  Title  Office

Mergers & Acquisitions

  • Represented Boston Biomedical, Inc. (BBI) in its sale to Dainippon Sumitomo Pharma Co., Ltd. (DSP) for up to $2.63 billion in total, which included $200 million upfront, up to $540 million in development milestone payments, and up to $1.89 billion in sales milestone payments.
  • Represented AIM listed special purpose acquisition company (SPAC) International Consolidated Minerals, Inc., formerly Platinum Diversified Mining, Inc., in its $250 million acquisition of International Consolidated Minerals Limited.
  • Represented Navios Maritime Acquisition Corporation in its $457.7 million acquisition of assets.
  • Represented QIAGEN NV in its $1.6 billion acquisition of Digene Corporation, including antitrust aspects of the transaction.
  • Represented China-based BioDuro, LLC in its $77 million acquisition by Pharmaceutical Product Development, Inc.
  • Represented Vertex Pharmaceuticals, Inc. in its $400 million acquisition of ViroChem Pharma, Inc.
  • Served as special US counsel to Nippon Sheet Glass Co., Ltd. in its $3.5 billion acquisition of Pilkington, PLC.
  • Represented the general counsel of a homeland security company being acquired in a multibillion-dollar transaction. During the due diligence phase of the acquisition, the acquiring company discovered bribes paid to officials in West Africa. This matter was resolved successfully for our client despite charges being made against additional individuals associated with the company.
  • Represented a US-based international company regarding the potential purchase of a European company and structuring of a deal to account for indemnification obligations, insurance related issues, and coverage for representations and warranties.

Securities

  • Represented Navios Maritime Acquisition Corporation (NYSE: NNA.U) in its $90 million public offering in August 2010. Among the many offerings that we have done for Navios and its affiliates, in 2008, we completed Navios’s IPO of approximately $253 million, which made Navios the first SPAC initially listed on the NYSE.
  • Represented GI Dynamics, Inc. (ASX: GID) in the filing of its Australian IPO and contemporaneous US private placement, which raised a combined $85 million in September 2011.

White Collar Criminal Defense & Parallel Proceedings

  • Advised a large, multinational corporation contemplating a cross-border acquisition on FCPA issues arising in the due diligence performed by a “Big 4” consulting firm. We analyzed the findings and assisted the client in fully evaluating the acquisition opportunity. Resulted in better offer for our client.
  • Advised a number of Russian companies regarding the potential application of the UK Bribery Act.
  • Conducted an audit of a Canada-based global mobile communications company’s FCPA compliance program.
  • Conducted an investigation and advised a subsidiary of a public company regarding entertainment-related red flags in the marketing of national security technology to a North African government agency.
  • Counseled European subsidiaries and the US parent of a major chemical company regarding EU and French criminal investigations and related liability and (CGL and D&O) coverage issues
  • Regularly provide training and legal advice to the executives and employees of numerous US and UK companies regarding the FCPA and the UK Bribery Act and other international anticorruption laws.
  • Represented a manager of a Dutch petroleum services company in connection with an FCPA investigation, led by the DOJ in Washington, DC, relating to construction contracts in Latin America. Although the international company ultimately paid a fine, our client was not charged.
  • Represented a technology company in conducting FCPA due diligence for a proposed merger, with a specific focus on issues relating to a distributorship in China.

Representative Clients

  • Dräger
  • Adlens Ltd.
  • Crawford Healthcare Holdings Limited
  • Evotec AG
  • GreatPoint Energy
  • iMDsoft
  • Neurimmune Therapeutics AG
  • NICE Systems
  • NovImmune SA
  • QIAGEN N.V.
  • Retroscreen Virology
  • Roche
  • Rosetta Genomics Ltd.
  • Royalty Pharma
  • SkyePharma PLC
  • Teva
  • Virgin Atlantic Airways Ltd.
  • XenoPort, Inc.

Past